Cheryl Scott

3 days ago | bioprocessintl.com | Cheryl Scott

Rapid advancement of gene therapy has driven a surge in demand for clinical-grade viral vectors. Can the industry meet that demand with manufacturing capacity? The short answer is “Yes – and then some!”As part of the cell and gene therapy track on day three of BPI Europe – held in Hamburg, Germany, this past May – Andrew Harmon of Latham BioPharm Group (part of Sia Partners) presented an approach for modeling biopharmaceutical market demand.

2 months ago | bioprocessintl.com | Cheryl Scott |Jason Beckwith |Stephen Goldrick |Chad Hafer

Cheryl Scott, Editor in Chief. In publishing, the general rule of thumb is for magazines to undergo a redesign process every five years or so. Longtime BPI subscribers will know that it’s been more than that for us — although our website has been fully refreshed recently. Perhaps that is a sign of the times, and maybe it has something to do with our relatively stable editorial staff and its comfort level with familiar designs.

2 months ago | bioprocessintl.com | Cheryl Scott |Daria Marsh |Chandan K. Sen |Matthew Lakelin

BPI West in San Diego, CA, continues to be my personal favorite conference to attend every year. The location can’t be beat — not least because it’s in zone and saves me from jet lag — but it’s so much more than that. It’s the program, the food, the west-coast vibe, the just-the-right-size crowd . . . and this year, I have to say that the posters in our exhibit hall were the highlight of my week.

2 months ago | bioprocessintl.com | Cheryl Scott

BioProcess International's Editor in Chief, Cheryl Scott, interviews 1st place poster hall winner, Eashwar Rajaraman, principal scientist at Biologics Research Center of Novartis. His team's poster “Iterative design of a DSP Work Package for Multispecifics: Learnings and Adaptations,” summarizes lessons learned in developing a platform-like approach to downstream processing of multispecific molecules.

Mar 6, 2025 | bioprocessintl.com | Cheryl Scott |Olena Chervonenko |Mike King |Philip Johnson

In nearly 30 years of working as an editor covering the biopharmaceutical industry, first with BioPharm and later as cofounder of BioProcess International, I’ve copyedited thousands of articles. From business and regulatory discussions to technical reports and reviews, sponsored “advertorial” pieces, and beyond, I’ve seen it all in relation to the biopharmaceutical industry. Some papers, however, have stuck with me more than others, and one in particular comes to mind often lately.